This advisory group was active from April 2021-March 2022.
This article highlights five myths about treatment for OUD, provides context regarding current guidance, and offers suggestions for how managed care organizations (MCOs) can support care for patients with addiction through a chronic health model.
AMCP supports regulatory and legislative provisions relating to opioid management that ensure appropriate patient access and treatment of uncontrolled pain, while limiting abuse and diversion of opioids and opioid potentiators. .
Recognizing the widespread and devastating nature of the opioid crisis, AMCP formed the Addiction Treatment Advisory Group in 2015 based on the recommendation from the AMCP Partnership Forum, Breaking the Link between Pain Management and Opioid Use Disorder.
Press Release: Opioid Prescribing in Georgia Medicaid Program: Potentially Inappropriate Practices are Increasing, According to a Study in JMCP
AMCP letter to E&C Chairman Walden and Ranking Member Pallone
Press Release: AMCP Launches New Addiction Advisory Group (AAG) to Address Opioid Crisis Through Promotion of Best Practices, Innovative Care Models and Benefit Designs
AMCP comments supporting state legislation allowing insurers access to the PDMP.
AMCP webinar that discussed current ASAM guidelines and other clinical guidance regarding MAT.
AMCP webinar that discussed current ASAM guidelines and other clinical guidance regarding MAT.
AMCP webinar that reviewed the AMCP Addiction Treatment Advisory Group (ATAG) recommendations to improve access to medication-assisted treatment and naloxone.
AMCP webinar that reviewed the AMCP Addiction Treatment Advisory Group (ATAG) recommendations to improve access to medication-assisted treatment and naloxone.
